Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials

被引：3

作者：

Clumeck, N. ^{[1
]}

Cahn, P. ^{[2
]}

Molina, J-M ^{[3
,4
]}

Mills, A.

Nijs, S. ^{[5
]}

Vingerhoets, J. ^{[5
]}

Witek, J. ^{[6
]}

机构：

[1] St Pierre Univ Hosp, Div Infect Dis, B-1000 Brussels, Belgium

[2] Fdn Huesped, Buenos Aires, DF, Argentina

[3] St Louis Hosp, AP HP, Dept Infect Dis, Paris, France

[4] Univ Paris Diderot, Paris, France

[5] Tibotec BVBA, Beerse, Belgium

[6] Tibotec Inc, Titusville, NJ USA

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 2010年 / 21卷 / 11期

关键词：

etravirine; HIV-1; DUET; NNRTI; treatment-experienced; EXPERIENCED HIV-1-INFECTED PATIENTS; PLACEBO-CONTROLLED TRIAL; SOCIETY-USA PANEL; TMC125; ETRAVIRINE; HIV-1; INFECTION; DOUBLE-BLIND; EFFICACY; SAFETY; RECOMMENDATIONS;

D O I：

10.1258/ijsa.2010.010139

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The objective of this subanalysis of the Phase III DUET trials was to examine virological response to an etravirine-containing regimen in patients harbouring virus fully sensitive to etravirine. Full etravirine sensitivity was defined as fold change in 50% effective concentration (FC) <= 3 or weighted genotypic score <= 2. At Week 48 in the etravirine group, 74% of patients with etravirine FC <= 3 and 77% with etravirine genotypic score <= 2 had viral load <50 HIV-1 RNA copies/mL, versus 48% and 46%, respectively, in the placebo group (P < 0.0001). Response rates increased with baseline phenotypic sensitivity score, but were consistently higher with etravirine (56-82%) than placebo (2-72%). Similar observations were made in patients harbouring virus with full etravirine and darunavir sensitivity. Our findings support current recommendations to include three active agents in treatment-experienced patients' regimens.

引用

页码：738 / 740

页数：3

共 11 条

[1] Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection [J].

Cooper, David A. ;

Steigbigel, Roy T. ;

Gatell, Jose M. ;

Rockstroh, Jurgen K. ;

Katlama, Christine ;

Yeni, Patrick ;

Lazzarin, Adriano ;

Clotet, Bonaventura ;

Kumar, Princy N. ;

Eron, Joseph E. ;

Schechter, Mauro ;

Markowitz, Martin ;

Loutfy, Mona R. ;

Lennox, Jeffrey L. ;

Zhao, Jing ;

Chen, Joshua ;

Ryan, Desmond M. ;

Rhodes, Rand R. ;

Killar, John A. ;

Gilde, Lucinda R. ;

Strohmaier, Kim M. ;

Meibohm, Anne R. ;

Miller, Michael D. ;

Hazuda, Daria J. ;

Nessly, Michael L. ;

DiNubile, Mark J. ;

Isaacs, Robin D. ;

Teppler, Hedy ;

Nguyen, Bach-Yen .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :355-365

[2]

DEMEYER S, 2008, 6 EUR HIV DRUG RES W

[3] British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 [J].

Gazzard, B. G. .

HIV MEDICINE, 2008, 9 (08) :563-608

[4] Antiretroviral drug resistance testing in adult HIV-1 infection:: 2008 recommendations of an International AIDS Society-USA panel [J].

Hirsch, Martin S. ;

Guenthard, Huldrych F. ;

Schapiro, Jonathan M. ;

Brun-Vezinet, Francoise ;

Clotet, Bonaventura ;

Hammer, Scott M. ;

Johnson, Victoria A. ;

Kuritzkes, Daniel R. ;

Mellors, John W. ;

Pillay, Deenan ;

Yeni, Patrick G. ;

Jacobsen, Donna M. ;

Richman, Douglas D. .

CLINICAL INFECTIOUS DISEASES, 2008, 47 (02) :266-285

[5] Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials [J].

Katlama, Christine ;

Haubrich, Richard ;

Lalezari, Jacob ;

Lazzarin, Adriano ;

Madruga, Jose V. ;

Molina, Jean-Michel ;

Schechter, Mauro ;

Peeters, Monika ;

Picchio, Gaston ;

Vingerhoets, Johan ;

Woodfall, Brian ;

De Smedt, Goedele .

AIDS, 2009, 23 (17) :2289-2300

[6] Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial [J].

Lazzarin, Adriano ;

Campbell, Thomas ;

Clotet, Bonaventura ;

Johnson, Margaret ;

Katlama, Christine ;

Moll, Arend ;

Towner, William ;

Trortier, Benoit ;

Peeters, Monika ;

Vingerhoets, Johan ;

de Smedt, Goedele ;

Baeten, Benny ;

Beets, Greet ;

Sinha, Rekha ;

Woodfall, Brian .

LANCET, 2007, 370 (9581) :39-48

[7] Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial [J].

Madruga, Jose Valdez ;

Cahn, Pedro ;

Grinsztejn, Beatriz ;

Haubrich, Richard ;

Lalezari, Jacob ;

Mills, Anthony ;

Pialoux, Gilles ;

Wilkin, Timothy ;

Peeters, Monika ;

Vingerhoets, Johan ;

de Smedt, Goedele ;

Leopold, Lorant ;

Trefiglio, Roberto ;

Woodfall, Brion .

LANCET, 2007, 370 (9581) :29-38

[8]

PICCHIO G, 2010, 18 INT AIDS C VIENN

[9] Antiretroviral Treatment of Adult HIV Infection 2010 Recommendations of the International AIDS Society-USA Panel [J].

Thompson, Melanie A. ;

Aberg, Judith A. ;

Cahn, Pedro ;

Montaner, Julio S. G. ;

Rizzardini, Giuliano ;

Telenti, Amalio ;

Gatell, Jose M. ;

Guenthard, Huldrych F. ;

Hammer, Scott M. ;

Hirsch, Martin S. ;

Jacobsen, Donna M. ;

Reiss, Peter ;

Richman, Douglas D. ;

Volberding, Paul A. ;

Yeni, Patrick ;

Schooley, Robert T. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (03) :321-333

[10] Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies [J].

Vingerhoets, Johan ;

Tambuyzer, Lotke ;

Azijn, Hilde ;

Hoogstoel, Annemie ;

Nijs, Steven ;

Peeters, Monika ;

de Bethune, Marie-Pierre ;

De Smedt, Goedele ;

Woodfall, Brian ;

Picchio, Gaston .

AIDS, 2010, 24 (04) :503-514

← 1 2 →